SAS Institute hosted JMP Discovery Summit in San Diego September 15-17. Both of Adsurgo’s contributed papers were the top rated sessions by over 350 conference attendees. See the conference details here.
Abstract: Harness the Power of JMP®: Big Data and Social Media for Competitor Analytics
JMP for Competitive Intelligence with Text Analytics
Relative to the global population, there are now twice as many sensors (e.g., smartphones) in the Internet of Things and an equivalent number of social media accounts. The resultant explosive growth in data volume represents great opportunities for those who can find a signal in this vast collection of unstructured and uncertain noise. A recent project presented the need for JMP users to efficiently search and analyze large volumes of open source material on innovative technologies, associated maturity levels, current applications and primary competitors. Unique challenges included the need to extract the text from these diverse website architectures (absent the extraneous code) and from attached PDFs and PowerPoint files that are not always in a usable format. Once the corpus was developed, the text was imported into JMP to quickly identify critical themes of interest and associated documents. These steps were accomplished using an intuitive JMP interface to text mining routines in R. Text analytics using JMP data visualization, cluster analysis and decision tree capabilities enabled better characterization
of the market over traditional methods. This talk will demonstrate a series of JMP scripts and platforms to intelligently search scores of relevant websites and monitor social media outlets (such as Twitter), assemble a large collection of unstructured data, and answer focused research questions. Get paper here.
Abstract: JMP® for Biosimilars: Tools for Analytical Similarity
The Biologics Price Competition and Innovation Act of 2009 (BPCI Act) created an abbreviated pathway for licensing biological drug products that are shown to be biosimilar to reference drug products already licensed by the FDA. A biosimilar product is one that is “highly similar to the reference product notwithstanding minor differences in clinically inactive components.” Although this pathway to licensing provides an expedited means to
bringing biosimilar drugs to market for patients, it still requires the development and submittal of knowledge about the safety and effectiveness of the drug. Drug manufacturers are not only expected to develop the biosimilar drug, but also the analytical methods used to test the quality attributes of the drugs. These analytical methods are also used to prove analytical similarity between the biosimilar and the reference product. It has been stated by the FDA that this comparative “analytical characterization serves as the foundation of the biosimilar development program.” Although the use of statistical equivalence is well-published and understood, the development of acceptance criteria for these studies is not. In fact, the first biologics licensing application (BLA) for a biosimilar was reviewed in January 2015. This talk will provide an overview of the FDA’s current thinking on comparative analytical characterization, then illustrate how JMP can be used to conduct a test of statistical equivalence including the development of acceptance criteria.
Learn more here.